Definitive Contract 75N93022C00020
Award Date
7/5/22
Potential Completion Date
11/30/23
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Antagen Biosciences Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Canton, MA 02021, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This federal contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals. The $599,997.00 contract is a Firm Fixed Price Definitive Contract under the SBIR Program Phase I Action for the Major Program Code DAIDS. The purpose of the contract is to evaluate and modulate the molecular pathways involved in regulating and...
Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, has been awarded a $299,998 firm fixed price Small Business Innovation Research (SBIR) contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Antagen will further develop its novel protein nanoparticle-based expression and delivery system using FcRider technology and antibody afucosylation technology to produce an engineered HIV envelope glycoprotein...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $300,000 firm fixed price definitive contract to Nference Inc., a for-profit organization located in Cambridge, Massachusetts, to deliver on SBIR Topic 111 with a completion date of September 15, 2023. No set-aside designation was used for this award. The contract will support the National Institute of Allergy and Infectious Diseases' mission to conduct and...
The Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $599,980 firm fixed price contract to Tendel Therapies, Inc., a small business, for research and development services related to genetic adjuvants to promote durable anti-influenza stem antibodies in older adults. This contract was awarded under the NIH and Centers for Disease Control and Prevention's Small Business Innovation Research (SBIR) program,...
This $1,000,000 firm-fixed-price SBIR Phase II contract was awarded by the Centers for Disease Control and Prevention (CDC) to Antagen Biosciences Inc., a minority-owned, small disadvantaged business. The contract is for research and development of an engineered HIV envelope glycoprotein and novel vaccine adjuvants to enhance the efficacy of vaccines against infectious and immune-mediated diseases. This award is part of Antagen's broader portfolio of SBIR contracts, including prior awards from...
This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a "Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals", which aligns with...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awarded a $298,596 definitive contract to Sanaria Inc. of Potomac, MD for Research Type Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from August 30, 2022 through April 1, 2024. The place of performance is Potomac, MD and the contract has a total small business set aside...
This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $11,502.40 purchase order to New England Biolabs, Inc. for biological supplies and reagent kits. The firm fixed price order is for the delivery of these products to Ipswich, Massachusetts between August 29 and October 15, 2023. As the prime contractor, New England Biolabs will supply the requested biological supplies and reagents to support the National...